FR2778851B1 - COMPOSITION BASED ON CYSTEINE PROTEASE INHIBITORS FOR DELAYING SENESCENCE, SELF-DESTRUCTION AND HEMOLYSIS OF ERYTHROCYTES - Google Patents

COMPOSITION BASED ON CYSTEINE PROTEASE INHIBITORS FOR DELAYING SENESCENCE, SELF-DESTRUCTION AND HEMOLYSIS OF ERYTHROCYTES

Info

Publication number
FR2778851B1
FR2778851B1 FR9806288A FR9806288A FR2778851B1 FR 2778851 B1 FR2778851 B1 FR 2778851B1 FR 9806288 A FR9806288 A FR 9806288A FR 9806288 A FR9806288 A FR 9806288A FR 2778851 B1 FR2778851 B1 FR 2778851B1
Authority
FR
France
Prior art keywords
hemolysis
erythrocytes
destruction
self
protease inhibitors
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
FR9806288A
Other languages
French (fr)
Other versions
FR2778851A1 (en
Inventor
Jean Claude Ameisen
Daniela Bratosin
Jerome Estaquier
Jean Jacques Huart
Jean Montreuil
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
AETSRN
Association pour lEssor de la Transfusion Sanguine dans la Region Nord
Original Assignee
AETSRN
Association pour lEssor de la Transfusion Sanguine dans la Region Nord
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by AETSRN, Association pour lEssor de la Transfusion Sanguine dans la Region Nord filed Critical AETSRN
Priority to FR9806288A priority Critical patent/FR2778851B1/en
Publication of FR2778851A1 publication Critical patent/FR2778851A1/en
Application granted granted Critical
Publication of FR2778851B1 publication Critical patent/FR2778851B1/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/07—Tetrapeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/18—Erythrocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/06—Tripeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hematology (AREA)
  • Cell Biology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Organic Chemistry (AREA)
  • Developmental Biology & Embryology (AREA)
  • Diabetes (AREA)
  • Virology (AREA)
  • Zoology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
FR9806288A 1998-05-19 1998-05-19 COMPOSITION BASED ON CYSTEINE PROTEASE INHIBITORS FOR DELAYING SENESCENCE, SELF-DESTRUCTION AND HEMOLYSIS OF ERYTHROCYTES Expired - Fee Related FR2778851B1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
FR9806288A FR2778851B1 (en) 1998-05-19 1998-05-19 COMPOSITION BASED ON CYSTEINE PROTEASE INHIBITORS FOR DELAYING SENESCENCE, SELF-DESTRUCTION AND HEMOLYSIS OF ERYTHROCYTES

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR9806288A FR2778851B1 (en) 1998-05-19 1998-05-19 COMPOSITION BASED ON CYSTEINE PROTEASE INHIBITORS FOR DELAYING SENESCENCE, SELF-DESTRUCTION AND HEMOLYSIS OF ERYTHROCYTES

Publications (2)

Publication Number Publication Date
FR2778851A1 FR2778851A1 (en) 1999-11-26
FR2778851B1 true FR2778851B1 (en) 2002-07-26

Family

ID=9526488

Family Applications (1)

Application Number Title Priority Date Filing Date
FR9806288A Expired - Fee Related FR2778851B1 (en) 1998-05-19 1998-05-19 COMPOSITION BASED ON CYSTEINE PROTEASE INHIBITORS FOR DELAYING SENESCENCE, SELF-DESTRUCTION AND HEMOLYSIS OF ERYTHROCYTES

Country Status (1)

Country Link
FR (1) FR2778851B1 (en)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11243218B2 (en) 2015-10-07 2022-02-08 Sangui Bio Pty Ltd. Blood preparation and profiling
US11693006B2 (en) 2016-12-20 2023-07-04 Sangui Bio Pty. Ltd Blood profiling with protease inhibitors

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017106899A2 (en) * 2015-12-22 2017-06-29 Sangui Bio Pty. Ltd Therapeutic methods using erythrocytes

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8815962D0 (en) * 1988-07-05 1988-08-10 Univ London Pharmaceutical preparation & method for promoting reinnervation of muscle fibers
US5736520A (en) * 1988-10-07 1998-04-07 Merrell Pharmaceuticals Inc. Peptidase inhibitors
AU644621B2 (en) * 1989-12-18 1993-12-16 Transgene S.A. Pharmaceutical composition for treating or preventing retroviral infections
EP0580161A1 (en) * 1992-07-22 1994-01-26 THE McLEAN HOSPITAL CORPORATION Prophylactic and therapeutic treatment of Alzheimer's disease
US5607831A (en) * 1993-03-25 1997-03-04 The United States Of America As Represented By The Department Of Health And Human Services In vitro methods for assessing the susceptibility of HIV-1-infected individuals to cysteine protease-mediated activation-induced programmed cell death

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11243218B2 (en) 2015-10-07 2022-02-08 Sangui Bio Pty Ltd. Blood preparation and profiling
US11693006B2 (en) 2016-12-20 2023-07-04 Sangui Bio Pty. Ltd Blood profiling with protease inhibitors

Also Published As

Publication number Publication date
FR2778851A1 (en) 1999-11-26

Similar Documents

Publication Publication Date Title
NO990548D0 (en) Inhibitors of cysteine protease
IL112759A0 (en) Novel cysteine protease inhibitors
DE69716934T2 (en) 1,3-DIHETEROCYCLIC METALOPROTEASE INHIBITORS
HUP0600110A3 (en) Removal of plasmin(ogen)from protein solutions
NO20012980L (en) protease inhibitors
DE3789371D1 (en) Aryloxy and arylacyloxymethyl ketones as thiol protease inhibitors.
PT1086076E (en) SULFONAMIDE INHIBITORS OF ASPARTIL PROTEASE
WO2003016335A3 (en) Irreversible cysteine protease inhibitors of legumain
GB9917909D0 (en) Cysteine protease inhibitors
EP1021199A4 (en) PEPTIDE-CONTAINING $g(a)-KETOAMIDE CYSTEINE AND SERINE PROTEASE INHIBITORS
HUP9900390A3 (en) Serine protease inhibitors, and pharmaceutical compositions containing them
DK1077681T3 (en) Levothyroxine sodium-containing pharmaceutical composition
FR2778851B1 (en) COMPOSITION BASED ON CYSTEINE PROTEASE INHIBITORS FOR DELAYING SENESCENCE, SELF-DESTRUCTION AND HEMOLYSIS OF ERYTHROCYTES
NO20011388D0 (en) Hydroxamate-containing cysteine and serine protease inhibitors
DE69710193D1 (en) 6-Substituted amino-4-oxa-1-azabicyclo [3.2.0] heptan-7-one derivatives as cysteine protease inhibitors
ATE273307T1 (en) BENZO(5,6)CYCLOHEPTAPYRIDINE DERIVATIVES APPLICABLE AS FARNESYL PROTEIN TRANSFERASE INHIBITORS
DK0929577T3 (en) Stabilized proteinaceous protease inhibitors and variants thereof
DE29900913U1 (en) Suction and pouring vessel
ID24267A (en) ENANSIOMERS OF 4 - [[(SIANOIMINO) [(1,2,2-TRIMETHYLOPOPIL) AMINO] METHYL] AMINO] BENZONITRIL
ITBO990185A0 (en) METHOD FOR DETERMINING MITOCHONDRIAL FUNCTIONALITY AND RELATED KIT.
DK0906309T3 (en) Modified form of the R (-) - N- (4,4-di (3-methylthien-2-yl) but-3-enyl) nipecotinic acid hydrochloride
DK1087981T3 (en) prenyl transferase inhibitors
SI0936912T1 (en) Inhibitors of cysteine protease
UA3151S (en) "SIR JONES" TEA LABEL
UA2779S (en) SET OF LABELS "GOLD CUP"

Legal Events

Date Code Title Description
CL Concession to grant licences
TP Transmission of property
ST Notification of lapse

Effective date: 20140131